NCT02500641 2019-06-21
FORWARD
Menarini International Operations Luxembourg SA
Phase 4 Completed
Clinical Trials
9 trialsNCT00921375 2014-12-12
Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia
Virchow Group
Phase 3 Completed
NCT00628628 2013-08-01
Rasburicase in Patients at Risk for Tumor Lysis Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00230178 2010-01-12
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
Sanofi
Phase 3 Completed
NCT00631579 2009-10-02
Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma
Sanofi
Phase 2 Completed
NCT00302653 2009-09-25
Rasburicase in Tumor Lysis Syndrome
Sanofi
Phase 4 Completed
NCT00230217 2009-03-30
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
Sanofi
Phase 4 Completed
NCT00290992 2009-03-30
Rasburicase for Hyperuricemia
Sanofi
Phase 2 Completed
NCT00563771 2008-01-28
Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome
Sanofi
Phase 4 Completed